Digital Diagnostics AG ("Applicant" or "digid") requests the Director to exercise supervisory authority to prioritize the initial examination of Applicant's above-referenced trademark applications covering marks used to identify COVID-19 medical related goods and services. This petition is based on the attached Declaration of Mr. Mirsad Devic, Applicant's Chief Digital Officer (the "Devic Declaration"), and the exhibits thereto. As set forth in this petition and in the Devic Declaration, Applicant's trademark applications qualify for prioritized examination because Applicant seeks the registrations of its CANTISENSE and DIGID marks to identify, among other things, a medical device (pending approval by the United States Food and Drug Administration ("FDA")) for detecting the virus that causes COVID-19. For ease of reading, please see the attached PDF version of this petition and the Devic Declaration, both of which are submitted as "Evidence." Applicant is a healthtech startup based in Mainz and Berlin, Germany. Applicant's interdisciplinary team of experienced specialists from the fields of medicine, diagnostics, pharma, nanotech, artificial intelligence, and digitalization founded digid in 2019. digid aims to digitalize today's diagnostics solutions through the development of a proprietary, scalable system that combines sensorics, nanotech and A.I. and enables non-invasive, real-time tracking of human and animal biodata. Devic Declaration paragraph 2. Its mission is to bring the power of a laboratory to everyone's smartphone. Id., Ex. 1 at 4. digid is developing a digital diagnostics platform built upon its proprietary nanotech Cantisense biosensor technology and an ecosystem of mobile applications to enable real-time, A.I-powered diagnostics of human and animal biodata. Id. Applicant applied to register its CANTISENSE (No. 90010716) and DIGID word (No. 90011071) and design (No. 90011673) marks in connection with, among other related goods and services, medical devices such as diagnostic tests for the detection of the SARS-CoV-2 virus in patients suspected of COVID-19. Applicant develops and produces the Digid Cantisense SARS-CoV-2 Test, a specialized medical device for professional use that is based on digid's proprietary Cantisense biosensor technology. Id. paragraph 4. The Digid Cantisense SARS-CoV-2 Test determines within minutes whether a person is infected with the SARS-CoV-2 virus that causes COVID-19. Id. The FDA has made Applicant's Digid Cantisense SARS-CoV-2 Test available under an emergency access mechanism called an Emergency Use Authorization ("EUA") pursuant to section 564 of the Federal Food, Drug, and Cosmetic Act. Id. paragraph 5. The EUA is supported by the Secretary of Health and Human Service's declaration that circumstances exist to justify the emergency use of in vitro diagnostics for the detection and/or diagnosis of the virus that causes COVID-19. Applicant's "Fact Sheet for Healthcare Providers" informs health care providers of the known and potential risks and benefits of the emergency use of the Digid Cantisense SARS-CoV-2 Test to detect the SARS-CoV-2 virus in patients suspected of COVID-19. Id. paragraph 6, Ex. 2. On May 30, 2020, Applicant sought FDA approval (Code of Federal Regulations, Title 21) of its Digid Cantisense SARS-CoV-2 Test. Id. paragraph 7, Ex. 1 at 26-29. As of the date of this petition, digid's application remains in review. Id. paragraph 7. The pre-EUA number for Applicant's diagnostic test is PEUA201247. Id. In view of the foregoing, Applicant respectfully requests the prioritized initial examination of the above- referenced trademark applications for CANTISENSE (No. 90010716) and DIGID word (No. 90011071) and design (No. 90011673) marks. If further information is needed, please contact Applicant's attorney of record.